Could a daily probiotic protect your gut while traveling abroad?

NCT ID NCT07705659

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This trial investigates whether a probiotic supplement containing two strains of Bifidobacterium longum can help maintain gut health and reduce symptoms like digestive issues, respiratory problems, and poor well-being during short overseas trips (7 days or less). Healthy adults traveling from China to an overseas destination take one sachet of the probiotic or a placebo daily from departure until return. The study measures changes in gut bacteria, immune markers, and self-reported symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a probiotic supplement containing two strains of Bifidobacterium longum
What this could lead to
If it works, this could point toward a simple way to prevent travel-related gut and immune issues.
What could go wrong
This is a small early-stage trial with only 40 participants, so results may not apply broadly. The supplement may not outperform a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age: 18-65 years, inclusive, with no restriction on gender. 2. Planned short-term round-trip travel from China to an overseas destination, with a total travel duration of no more than 7 days. 3. Volunteers must be able to understand and comply with the study protocol, and provide written informed consent prior to initiation of any study procedures. Exclusion Criteria: 1. Diseases that may affect the evaluation of trial results, including but not limited to immune dysfunction, severe renal/hepatic impairment, severe cardiovascular disease, malignant tumors, acute or chronic infections, etc. 2. Use of probiotic preparations, antibiotics, hormones, immunosuppressants, biological agents, or JAK inhibitors within 4 weeks prior to enrollment. 3. Subjects with confirmed or uncontrolled parasitic infections. 4. ① Patients receiving long-term medication for chronic diseases; ② Patients with severe organic lesions of the thyroid, heart, brain, lungs, kidneys, or musculoskeletal system; ③ Patients with a history of or current psychiatric disorders; ④ Patients on long-term glucocorticoid therapy; ⑤ Patients using growth hormone, γ-aminobutyric acid, lysine, inositol, or vitamin B12. 5. Any uncontrolled, clinically significant laboratory abnormalities that, in the opinion of the investigator, may interfere with the interpretation of study data or the subject's ability to participate in the study. 6. Participation in other clinical intervention studies involving drugs, dietary supplements, probiotics, or prebiotics within the past 4 weeks. 7. Subjects with severe infection or severe trauma as determined by the investigator, or those who have undergone moderate to major surgery within the past month. 8. Known allergy to any components of the probiotic product. 9. Subjects deemed unsuitable for participation in this clinical study by the investigator for any other reason.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Changes in gut microbiota, gut metabolites, respiratory symptoms, and well-being index are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Signs and Symptoms, Respiratory

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.